FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2120160449> ?p ?o ?g. }

• W2120160449 endingPage "55" @default.
• W2120160449 startingPage "48" @default.
• W2120160449 abstract "With antiangiogenic agents, tumor shrinkage may be absent, despite survival benefit. The present study assessed the predictive value of molecular imaging for the identification of survival benefit during antiangiogenic treatment with bevacizumab and erlotinib in patients with advanced non–small cell lung cancer. <b>Methods:</b> Patients were evaluated using an imaging protocol including CT, ¹⁸F-FDG PET, H₂¹⁵O PET, and dynamic contrast-enhanced MRI to derive measurements on tumor size, glucose metabolism, perfusion, and microvascular permeability. The percentage change in imaging parameters after 3 wk of treatment as compared with baseline was calculated and correlated with progression-free survival (PFS). <b>Results:</b> Forty-four patients were included, and 40 underwent CT and ¹⁸F-FDG PET at both time points. Complete datasets, containing all imaging modalities, were available for 14 patients. Bevacizumab and erlotinib treatment resulted in decreased metabolism, perfusion, and tumor size. A decrease in standardized uptake value or tumor perfusion of more than 20% at week 3 was associated with longer PFS (9.7 vs. 2.8 mo, <i>P</i> = 0.01, and 12.5 vs. 2.9 mo, <i>P</i> = 0.009, respectively). Whole-tumor K^trans (the endothelial transfer constant) was not associated with PFS, but patients with an increase of more than 15% in the SD of tumor K^trans values—that is, an increase in regions with low or high K^trans values—after 3 wk had shorter PFS (2.3 vs. 7.0 mo, <i>P</i> = 0.008). A partial response, according to the response evaluation criteria in solid tumors (RECIST)<i>,</i> at week 3 was also associated with prolonged PFS (4.6 vs. 2.9 mo, <i>P</i> = 0.017). However, 40% of patients with a partial response as their best RECIST response still had stable disease at week 3. In these cases tumor perfusion was already decreased and K^trans heterogeneity showed no increase, indicating that the latter parameters seem to be more discriminative than RECIST at the 3-wk time point. <b>Conclusion:</b> PET and dynamic contrast-enhanced MRI were able to identify patients who benefit from bevacizumab and erlotinib treatment. Molecular imaging seems to allow earlier response evaluation than CT." @default.
• W2120160449 created "2016-06-24" @default.
• W2120160449 creator A5016567527 @default.
• W2120160449 creator A5016904876 @default.
• W2120160449 creator A5017680598 @default.
• W2120160449 creator A5019432691 @default.
• W2120160449 creator A5021902098 @default.
• W2120160449 creator A5031176507 @default.
• W2120160449 creator A5046995806 @default.
• W2120160449 creator A5051553539 @default.
• W2120160449 creator A5065110382 @default.
• W2120160449 creator A5066714040 @default.
• W2120160449 creator A5086285920 @default.
• W2120160449 creator A5087339777 @default.
• W2120160449 creator A5087967286 @default.
• W2120160449 date "2010-12-13" @default.
• W2120160449 modified "2023-09-27" @default.
• W2120160449 title "Monitoring Response to Antiangiogenic Therapy in Non–Small Cell Lung Cancer Using Imaging Markers Derived from PET and Dynamic Contrast-Enhanced MRI" @default.
• W2120160449 cites W1967670124 @default.
• W2120160449 cites W1969328947 @default.
• W2120160449 cites W1992168087 @default.
• W2120160449 cites W1995308403 @default.
• W2120160449 cites W2020905321 @default.
• W2120160449 cites W2042098439 @default.
• W2120160449 cites W2056586600 @default.
• W2120160449 cites W2068854404 @default.
• W2120160449 cites W2075351817 @default.
• W2120160449 cites W2081361368 @default.
• W2120160449 cites W2089513130 @default.
• W2120160449 cites W2092078486 @default.
• W2120160449 cites W2109134893 @default.
• W2120160449 cites W2120718661 @default.
• W2120160449 cites W2122298066 @default.
• W2120160449 cites W2125161228 @default.
• W2120160449 cites W2133989967 @default.
• W2120160449 cites W2138297714 @default.
• W2120160449 cites W2142167347 @default.
• W2120160449 cites W2143967388 @default.
• W2120160449 cites W2146404049 @default.
• W2120160449 cites W2147178092 @default.
• W2120160449 cites W2159439661 @default.
• W2120160449 cites W2164515699 @default.
• W2120160449 cites W2165760078 @default.
• W2120160449 cites W2166742462 @default.
• W2120160449 cites W2167241562 @default.
• W2120160449 cites W2169584638 @default.
• W2120160449 doi "https://doi.org/10.2967/jnumed.110.078261" @default.
• W2120160449 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21149474" @default.
• W2120160449 hasPublicationYear "2010" @default.
• W2120160449 type Work @default.
• W2120160449 sameAs 2120160449 @default.
• W2120160449 citedByCount "94" @default.
• W2120160449 countsByYear W21201604492012 @default.
• W2120160449 countsByYear W21201604492013 @default.
• W2120160449 countsByYear W21201604492014 @default.
• W2120160449 countsByYear W21201604492015 @default.
• W2120160449 countsByYear W21201604492016 @default.
• W2120160449 countsByYear W21201604492017 @default.
• W2120160449 countsByYear W21201604492018 @default.
• W2120160449 countsByYear W21201604492019 @default.
• W2120160449 countsByYear W21201604492020 @default.
• W2120160449 countsByYear W21201604492021 @default.
• W2120160449 countsByYear W21201604492022 @default.
• W2120160449 countsByYear W21201604492023 @default.
• W2120160449 crossrefType "journal-article" @default.
• W2120160449 hasAuthorship W2120160449A5016567527 @default.
• W2120160449 hasAuthorship W2120160449A5016904876 @default.
• W2120160449 hasAuthorship W2120160449A5017680598 @default.
• W2120160449 hasAuthorship W2120160449A5019432691 @default.
• W2120160449 hasAuthorship W2120160449A5021902098 @default.
• W2120160449 hasAuthorship W2120160449A5031176507 @default.
• W2120160449 hasAuthorship W2120160449A5046995806 @default.
• W2120160449 hasAuthorship W2120160449A5051553539 @default.
• W2120160449 hasAuthorship W2120160449A5065110382 @default.
• W2120160449 hasAuthorship W2120160449A5066714040 @default.
• W2120160449 hasAuthorship W2120160449A5086285920 @default.
• W2120160449 hasAuthorship W2120160449A5087339777 @default.
• W2120160449 hasAuthorship W2120160449A5087967286 @default.
• W2120160449 hasBestOaLocation W21201604491 @default.
• W2120160449 hasConcept C121608353 @default.
• W2120160449 hasConcept C126322002 @default.
• W2120160449 hasConcept C135691158 @default.
• W2120160449 hasConcept C142724271 @default.
• W2120160449 hasConcept C146957229 @default.
• W2120160449 hasConcept C199374082 @default.
• W2120160449 hasConcept C2775842073 @default.
• W2120160449 hasConcept C2776256026 @default.
• W2120160449 hasConcept C2776694085 @default.
• W2120160449 hasConcept C2777802072 @default.
• W2120160449 hasConcept C2778087573 @default.
• W2120160449 hasConcept C2779438470 @default.
• W2120160449 hasConcept C2989005 @default.
• W2120160449 hasConcept C71924100 @default.
• W2120160449 hasConceptScore W2120160449C121608353 @default.
• W2120160449 hasConceptScore W2120160449C126322002 @default.
• W2120160449 hasConceptScore W2120160449C135691158 @default.
• W2120160449 hasConceptScore W2120160449C142724271 @default.
• W2120160449 hasConceptScore W2120160449C146957229 @default.

• next